Prospective clinical study of early diagnosis and treatment for intravasclular large B-cell lymphoma (IVL)

UMIN ID: UMIN000001309

Registered date:11/08/2008

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: Intravascular large B -cell lymphoma: IVL
• Date of first enrollment: 2007/03/01
• Target sample size: 10
• Countries of recruitment: Japan
• Study type: Interventional
• Intervention(s): 2/3 reduced dose CHOP therapy following rituximab on course 1. Standard dose R-CHOP therapy on course 2 to 6. HDC/AHST if possible.

Outcome(s)

• Primary Outcome: Overall survival
• Secondary Outcome: CR rate, Adverse events, Correspondence rate between early clinical diagnosis and pathological diagnosis, Diagnostic rate of bone marrow and/or random skin biopsy, Time to treatment failure

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: 80years-old
• Gender: Male and Female
• Exclude criteria: 1, collagen vascular disease 2, Severe infectious disease 3, Pre-treatment history for lymphoma 4, HIV+, HTLV1+ or HBV-Ag+ 5, Physician's decision of inappropriateness

Related Information

• Primary Sponsor: Department of Hematology and Immunology, Kanazawa Medical University
• Secondary Sponsor: Hokuriku hematological tumor research group
• Source(s) of Monetary Support: Department of Hematology and Immunology, Kanazawa Medical University,self funding